Kidney disease affecting one in every 200 adults globally now has fundamentally updated treatment protocols that shift from symptom management to targeting underlying immune dysfunction. The most common form of glomerulonephritis, IgA nephropathy occurs when abnormal antibodies deposit in kidney filters, triggering progressive inflammation that can advance to end-stage renal disease within decades. The 2025 Kidney Disease: Improving Global Outcomes guidelines represent a paradigm shift toward precision medicine approaches. Rather than relying primarily on blood pressure control and general immunosuppression, clinicians now have evidence-based protocols targeting specific pathophysiological pathways. These include therapies addressing aberrant IgA1 glycosylation, complement system activation, and mucosal immune dysregulation that drive disease progression. The guidelines emphasize early intervention based on risk stratification using biomarkers beyond traditional proteinuria measurements. This approach acknowledges that IgA nephropathy manifests differently across populations, with genetic variants influencing disease severity and treatment response. From a longevity perspective, these developments are particularly significant given that kidney function decline accelerates cardiovascular mortality and reduces healthspan substantially. The shift toward mechanism-based treatment represents genuine progress in nephrology, moving beyond the historical approach of managing consequences to preventing progression. However, the guidelines acknowledge substantial limitations in current evidence, particularly regarding optimal treatment duration and long-term outcomes. Most pivotal trials followed patients for only 2-3 years, leaving questions about sustained efficacy and potential adverse effects of newer targeted therapies. The real-world implementation of these complex protocols also presents challenges for healthcare systems globally.